CD80 and neoplasm: The investigation reveals that the combination of ICAM‐1‐Dxd with B7‐H3‐CD3 bispecific antibodies not only demonstrates significant inhibitory effects on tumor growth and metastasis but also plays a vital role in reprogramming the tumor immune microenvironment in triple‐negative breast cancer.